Has Christie Regula, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,073 in general payments to Christie Regula, MD across 158 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christie Regula, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christie Regula, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christie Regula, MD

MOHS-Micrographic Surgery · Pittsburgh, PANPI 1093949752

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,453 of the $4,073 with a category attached, or 84.8%. It is spread thinly across 32 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations.

$4,073in general payments, 2019–2025

Across 158 payments — averaging $25.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$740
Galderma Laboratories, L.p.$665
Johnson & Johnson$310
Amgen$266
Sanofi$213
Pfizer$197
plus $2K from 26 others

What the payments were for

Speaking & faculty fees$45011%
Food & beverage$3,45385%
Education$1704%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	39	$740
Galderma Laboratories, L.p.	9	$665
Johnson & Johnson	12	$310
Amgen	7	$266
Sanofi	8	$213
Pfizer	10	$197
E.r. Squibb & Sons, L.L.C.	11	$159
Novartis	6	$138
Sun Pharmaceutical Industries Inc.	2	$127
Revance Therapeutics, Inc.	1	$114
Prugen, Inc. Pharmaceuticals	2	$111
Incyte Corporation	4	$98
Merz North America, Inc.	5	$88
Bristol Myers Squibb	4	$87
Regeneron	2	$84
Biofrontera Inc.	5	$80
Dermira, Inc.	2	$65
UCB, Inc.	3	$63
Organogenesis Inc.	3	$63
Mayne Pharma Commercial LLC	5	$61
LEO Pharma Inc.	3	$60
Verrica Pharmaceuticals Inc.	2	$43
Regeneron Healthcare Solutions, Inc.	2	$41
Medtronic	1	$34
Ortho Dermatologics, A Division Of Bausch Health US, LLC	2	$31
Aclaris Therapeutics, Inc.	2	$30
Dermavant Sciences, Inc.	1	$22
Journey Medical Corporation	1	$22
VYNE Pharmaceuticals Inc.	1	$21
Kyowa Kirin, Inc.	1	$17
Genentech USA, Inc.	1	$16
Almirall LLC	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DAXXIFY$114
ILUMYA$108
Otezla$105

How this compares

$4,073 in reported general payments places this provider in the 70th percentile of 48 mohs-micrographic surgery providers in Pennsylvania.

See all mohs-micrographic surgery providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$238,451

Medicare patients

312

Services billed

1,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Doxycycline Hyclate	127	$850
Cephalexin	21	$610
Mupirocin	18	$219
ValacyclovirValacyclovir Hcl	19	$98

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Pittsburgh

Justin VujevichPittsburgh$6K
Preetha AgarwalPittsburgh$6K
Melissa Pugliano-MauroPittsburgh$3K
Geoffrey LimPittsburgh$1K
David BrodlandPittsburgh$387
John ZitelliPittsburgh$259
Amarachi EseonuPittsburgh$91
Gregory FulchieroAltoona$24K
Jason SchoenfeldPhiladelphia$20K
Cynthia BartusAllentown$10K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →